TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TAVR still a safe treatment option for immunocompromised patients
While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.
Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR
The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.
3-in-1 TAVR guidewire linked to faster procedures, less radiation
The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition.
AI has already transformed TAVR care—and the best is yet to come
Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning.
Waiting is no longer ‘good medicine’: Data shows treating severe AS with TAVR before symptoms appear improves outcomes, reduces costs
TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.

ESC Congress 2022 European Society of Cardiology

6 key sessions from ESC Congress 2022: TAVR mortality, AI vs. sonographers, radial vs. femoral access and more

ESC Congress 2022, the annual meeting of the European Society of Cardiology, was jam-packed with eye-opening new research from many of the leading voices in cardiovascular and vascular medicine. These six sessions were just some of the weekend's many highlights.

The Abbott Cephea transcatheter mitral valve replacement (TMVR) system.

Cardiologist praises updated design of new TMVR system after historic interventional procedure

A care team with the Sanger Heart & Vascular Institute has shared details about its recent successes in TMVR and TAVR. Cardiologist Michael Rinaldi, MD, highlighted the importance of having "a coordinated team of specialists with expertise in treating valve diseases."

What to expect at the TCT MedTech Innovation Forum during TCT 2022

The all-day summit, a collaboration between CRF and Fogarty Innovation, will focus on advances in healthcare technologies and patient care.

Three systems for left ventricular pacing during TAVR, modified TAVR valve delivery wire, the Opsens Savvy wire, and the Teleflex Wattson wire.

VIDEO: Use of temporary left ventricular pacing during TAVR procedures

Philippe Genereux, MD, medical director of the structural heart disease program at Morristown Medical Center, discusses the various options used for temporary pacing of the heart during transcatheter aortic valve replacement (TAVR) procedures.

TAVR programs follow inconsistent DNR policies, potentially skewing data

Not all hospitals respect the written preferences of patients, possibly motivated by a desire to report better TAVR outcomes.

Moderate aortic stenosis linked to a significant risk of death—should earlier interventions be considered?

Researchers tracked data from more than 12,000 moderate AS patients who originally participated in one of 25 different studies. While the findings seem to suggest earlier treatment could be beneficial for certain high-risk patients, additional research is still required.

SAPT after TAVR preferred over DAPT, new meta-analysis confirms

An international team of researchers, led by specialists from Cleveland Clinic, found that DAPT was consistently linked to a greater risk of major or life-threatening bleeding events.

Cardiac surgeons gaining procedural volume despite TAVR making up 84% of cases

A decade ago, when TAVR was first cleared by the FDA, surgeons had concern about losing business. But unexpectedly, TAVR has helped also gain heart surgery cases.

TAVR

TAVR still a safe treatment option for immunocompromised patients

Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR

3-in-1 TAVR guidewire linked to faster procedures, less radiation

AI has already transformed TAVR care—and the best is yet to come

Waiting is no longer ‘good medicine’: Data shows treating severe AS with TAVR before symptoms appear improves outcomes, reduces costs